<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Monopar Therapeutics Inc — News on 6ix</title>
    <link>https://6ix.com/company/monopar-therapeutics-inc</link>
    <description>Latest news and press releases for Monopar Therapeutics Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Sun, 19 Apr 2026 23:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/monopar-therapeutics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68359bfa78dffbe2df106f85.webp</url>
      <title>Monopar Therapeutics Inc</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc</link>
    </image>
    <item>
      <title>Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-presents-phase-3-data-showing-greater-neurologic-benefit-with-alxn1840-vs-soc-in-wilson-disease-patients-with-neurologic-symptoms-at-aan-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-presents-phase-3-data-showing-greater-neurologic-benefit-with-alxn1840-vs-soc-in-wilson-disease-patients-with-neurologic-symptoms-at-aan-2026</guid>
      <pubDate>Sun, 19 Apr 2026 23:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in Wilson disease patients with neurologic symptoms at baseline. The data will be pr</description>
    </item>
    <item>
      <title>Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
      <pubDate>Fri, 27 Mar 2026 17:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments. “2025 was a productive year for Monopar, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sh</description>
    </item>
    <item>
      <title>Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-expands-leadership-team-with-appointment-of-seasoned-biopharma-executive-susan-rodriguez-as-chief-commercial-and-strategy-officer</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-expands-leadership-team-with-appointment-of-seasoned-biopharma-executive-susan-rodriguez-as-chief-commercial-and-strategy-officer</guid>
      <pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical‐stage biopharmaceutical</description>
    </item>
    <item>
      <title>Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-therapeutics-reports-third-quarter-2025-financial-results-and-recent</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-therapeutics-reports-third-quarter-2025-financial-results-and-recent</guid>
      <pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical</description>
    </item>
    <item>
      <title>Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-presents-new-data-and-analyses-rapidly-improved-copper-balance-wilson-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-presents-new-data-and-analyses-rapidly-improved-copper-balance-wilson-disease</guid>
      <pubDate>Sun, 09 Nov 2025 05:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical</description>
    </item>
    <item>
      <title>Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-announces-abstract-accepted-oral-presentation-aasld-liver-meetingr-2025-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-announces-abstract-accepted-oral-presentation-aasld-liver-meetingr-2025-2025</guid>
      <pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical</description>
    </item>
    <item>
      <title>Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-announces-journal-hepatology-publishes-physicians-letter-editor-demonstrating</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-announces-journal-hepatology-publishes-physicians-letter-editor-demonstrating</guid>
      <pubDate>Tue, 23 Sep 2025 04:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical</description>
    </item>
    <item>
      <title>Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-therapeutics-inc-announces-pricing-135-million-underwritten-offering-common</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-therapeutics-inc-announces-pricing-135-million-underwritten-offering-common</guid>
      <pubDate>Tue, 23 Sep 2025 04:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a</description>
    </item>
    <item>
      <title>Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-present-long-term-neurological-120000375</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-present-long-term-neurological-120000375</guid>
      <pubDate>Sun, 14 Sep 2025 12:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease will be presented at the 150th American Neurological Association (ANA) Annual Meeting on September 14</description>
    </item>
    <item>
      <title>Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-announces-abstract-accepted-distinction-oral-and-poster-presentations</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-announces-abstract-accepted-distinction-oral-and-poster-presentations</guid>
      <pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical</description>
    </item>
    <item>
      <title>Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-therapeutics-reports-second-quarter-2025-financial-results-and-recent</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-therapeutics-reports-second-quarter-2025-financial-results-and-recent</guid>
      <pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical</description>
    </item>
    <item>
      <title>Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-and-ednoc-announce-expanded-access-program-mnpr-101-zr-and-mnpr-101-lu</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-and-ednoc-announce-expanded-access-program-mnpr-101-zr-and-mnpr-101-lu</guid>
      <pubDate>Wed, 11 Jun 2025 04:00:00 GMT</pubDate>
      <description>WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “us” and “our”) (Nasdaq: MNPR), a</description>
    </item>
    <item>
      <title>Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-therapeutics-announces-inclusion-russell-3000r-and-russell-2000r-indexes-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-therapeutics-announces-inclusion-russell-3000r-and-russell-2000r-indexes-2025</guid>
      <pubDate>Tue, 03 Jun 2025 04:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., June 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical</description>
    </item>
    <item>
      <title>Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-therapeutics-reports-first-quarter-2025-financial-results-and-recent</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-therapeutics-reports-first-quarter-2025-financial-results-and-recent</guid>
      <pubDate>Tue, 13 May 2025 04:00:00 GMT</pubDate>
      <description>WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical</description>
    </item>
    <item>
      <title>Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-presents-alxn1840-breaker-data-063000972</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-presents-alxn1840-breaker-data-063000972</guid>
      <pubDate>Wed, 07 May 2025 06:30:00 GMT</pubDate>
      <description>WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, one of the most prominent global conferences in l</description>
    </item>
    <item>
      <title>Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-announces-alxn1840-data-selected-late-breaker-presentation-easl-congress-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-announces-alxn1840-data-selected-late-breaker-presentation-easl-congress-2025</guid>
      <pubDate>Tue, 29 Apr 2025 04:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing</description>
    </item>
    <item>
      <title>Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent</guid>
      <pubDate>Mon, 31 Mar 2025 04:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing</description>
    </item>
    <item>
      <title>Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-therapeutics-inc-announces-pricing-40-million-public-offering-common-stock</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-therapeutics-inc-announces-pricing-40-million-public-offering-common-stock</guid>
      <pubDate>Fri, 20 Dec 2024 05:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology</description>
    </item>
    <item>
      <title>Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-announces-first-patient-dosed-its-novel-therapeutic-radiopharmaceutical-mnpr</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-announces-first-patient-dosed-its-novel-therapeutic-radiopharmaceutical-mnpr</guid>
      <pubDate>Thu, 05 Dec 2024 05:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing</description>
    </item>
    <item>
      <title>Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference</title>
      <link>https://6ix.com/company/monopar-therapeutics-inc/news/monopar-present-36th-annual-piper-sandler-healthcare-conference-2024-12-03</link>
      <guid isPermaLink="true">https://6ix.com/company/monopar-therapeutics-inc/news/monopar-present-36th-annual-piper-sandler-healthcare-conference-2024-12-03</guid>
      <pubDate>Tue, 03 Dec 2024 05:00:00 GMT</pubDate>
      <description>WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing</description>
    </item>
  </channel>
</rss>